Tirzepatide for weight loss in kidney transplant patients
Treatments studied
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests if tirzepatide can help people who have had a kidney transplant and are still overweight lose weight. It may be an option if you have had your transplant at least a year ago, your kidney function is stable, and your body mass index is 27 or higher.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You received a kidney transplant at least 12 months ago.
- Your body mass index (BMI) is 27 or higher, which is considered overweight or obese.
- Your kidney function has been stable over the past 3 months (a simple blood test checks this).
- Your anti-rejection medicines have not been changed recently.
- You are able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called tirzepatide, given as an injection, to see if it can improve daily function and symptoms in people with a weak heart (heart failure with reduced ejection fraction) who also have obesity. Tirzepatide works on two natural hormones to help with weight and may also improve heart health.
This trial tests a medication called tirzepatide (brand name Spartina) to see if it is safe and helpful for people with chronic kidney failure. The goal is to understand if this medicine can improve outcomes for patients with kidney problems who also have diabetes or are overweight.
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This trial tests the safety and effectiveness of tirzepatide, a once-weekly injection, for weight loss in people with obesity. It might be an option if you have a BMI of 27 or higher with weight-related health problems, or a BMI of 35 or higher, and live in or near Asunción, Paraguay.
Hear when a new Tirzepatide trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.